Navigation Links
New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
Date:9/16/2009

NEWNAN, Ga., Sept. 16 /PRNewswire/ -- CeloNova BioSciences, Inc. today announced that Franco Orsi, MD, PhD, will make two presentations at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference about "micro-bland embolization" which has demonstrated excellent clinical results in treating liver cancer. Professor Orsi and his colleagues at the European Institute of Oncology in Milan, Italy have developed a technique to cut off the blood supply inside liver tumors and liver metastases that leads to effective tumor control and reduced recurrence of tumors without the use of chemotherapy drugs.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090916/CL76973)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b)

"Embolic particles should be size-calibrated with a small bandwidth in diameter variations because during administration, larger particles within the same vial or syringe may occlude micro-vessels more proximally and prevent a deeper penetration of the smaller ones," reports Professor Orsi, whose findings will be presented at the CIRSE medical conference September 19-23 and published in the September edition of Vascular Disease Management.

"We are gratified that Dr. Orsi has developed this micro-bland embolization technique and demonstrated that the unique and very precise calibration of Embozene(TM) Microspheres leads to superior clinical findings in the treatment of liver cancer," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova Biosciences. "Embozene(TM) Microspheres, unlike other embolics, are precisely calibrated so that larger spheres do not prevent the deepest possible penetration of tumors. Patients with liver cancer treated in this new way can experience a longer life and a better quality of life."

About Embozene(TM) Microspheres

Embozene(TM) Microspheres are the first and only microspheres to be color-enhanced with a different color for each size for increased procedural safety, efficiency and visibility. They are also available in a wider range of sizes than any other spherical embolic on the market. CeloNova's Embozene(TM) Microspheres consist of a hydrogel core and an exterior shell made from Polyzene(R)-F, CeloNova's proprietary polymer which is known to be anti-inflammatory and bacterial-resistant. Four design features distinguish Embozene(TM) Microspheres from other spherical embolics: biocompatibility, precise calibration, stable suspension, and structural stability.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene(R)-F, a highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Both products are CE marked and Embozene(TM) Color Advanced microspheres have been approved by the US FDA. For more information, please visit www.celonova.com.

    CONTACT:
    Teresa Wilson
    CeloNova BioSciences, Inc.
    +1-678-895-6486
    +1-770-502-0304
    twilson@celonova.com


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
2. Chemoembolization Improving as Liver Cancer Treatment
3. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
4. Stenting Techniques Vie in Branchpoint Lesions
5. Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
6. Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology
7. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
8. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... MACRA replaces the outdated sustainable growth ... reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices from ... Market for MIPS Compliance Technology is Booming ... 3 or more clinicians seek to buy Merit-Based Incentive ... magnitude of the changes, the hunt is on for ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors ... its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will also ...
(Date:5/24/2017)... N.J. (PRWEB) , ... May 24, 2017 , ... ... Clara Maass Medical Center CEO Mary Ellen, hospital employees, and town officials to ... Belleville. , The facility was developed by Rendina as part of its ongoing ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... ... through innovative medical image management and interpretation, has received U.S. Food and Drug ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical image ...
(Date:5/24/2017)... DC (PRWEB) , ... May 24, 2017 , ... ... Center for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A ... formula for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines ...
Breaking Medicine News(10 mins):